These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF. Front Immunol; 2018; 9():3016. PubMed ID: 30619360 [Abstract] [Full Text] [Related]
3. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E. Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [Abstract] [Full Text] [Related]
4. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction. van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I. Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556 [Abstract] [Full Text] [Related]
6. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, Falkenburg JH. Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570 [Abstract] [Full Text] [Related]
12. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Blood; 2009 Oct 22; 114(17):3684-92. PubMed ID: 19706888 [Abstract] [Full Text] [Related]
13. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Blood; 1999 Apr 01; 93(7):2336-41. PubMed ID: 10090944 [Abstract] [Full Text] [Related]
14. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study. Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF. Leukemia; 2020 Mar 01; 34(3):831-844. PubMed ID: 31624377 [Abstract] [Full Text] [Related]
15. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP, Kester MG, Marijt WA, Goulmy E, Willemze R, Falkenburg JH. Leukemia; 2004 Apr 01; 18(4):798-808. PubMed ID: 14973499 [Abstract] [Full Text] [Related]
16. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH, Goulmy E. Haematologica; 2005 Oct 01; 90(10):1415-21. PubMed ID: 16219579 [Abstract] [Full Text] [Related]
17. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW, Falkenburg JH, Willemze R. Exp Hematol; 2003 Oct 01; 31(10):865-72. PubMed ID: 14550801 [Abstract] [Full Text] [Related]
18. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, van Luxemburg-Heys SA, Hoogeboom M, Mutis T, Drijfhout JW, van Rood JJ, Willemze R, Falkenburg JH. Proc Natl Acad Sci U S A; 2003 Mar 04; 100(5):2742-7. PubMed ID: 12601144 [Abstract] [Full Text] [Related]
19. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T. Leukemia; 2013 Mar 04; 27(3):642-9. PubMed ID: 23079962 [Abstract] [Full Text] [Related]
20. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD. Blood; 2008 Apr 01; 111(7):3884-92. PubMed ID: 18223170 [Abstract] [Full Text] [Related] Page: [Next] [New Search]